PE20171646A1 - Composiciones que comprenden 2-((1-(2(4-fluorofenil)-2-oxoetil)piperidin-4-il)metil)isoindolin-1-ona para tratar la esquizofrenia - Google Patents

Composiciones que comprenden 2-((1-(2(4-fluorofenil)-2-oxoetil)piperidin-4-il)metil)isoindolin-1-ona para tratar la esquizofrenia

Info

Publication number
PE20171646A1
PE20171646A1 PE2017000948A PE2017000948A PE20171646A1 PE 20171646 A1 PE20171646 A1 PE 20171646A1 PE 2017000948 A PE2017000948 A PE 2017000948A PE 2017000948 A PE2017000948 A PE 2017000948A PE 20171646 A1 PE20171646 A1 PE 20171646A1
Authority
PE
Peru
Prior art keywords
isoindolin
oxoethyl
piperidin
fluorophenyl
methyl
Prior art date
Application number
PE2017000948A
Other languages
English (en)
Inventor
Remy Luthringer
Masahiro Okuyama
Nadine Noel
Sandra Werner
Original Assignee
Minerva Neurosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minerva Neurosciences Inc filed Critical Minerva Neurosciences Inc
Publication of PE20171646A1 publication Critical patent/PE20171646A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Referido a una forma polimorfica A, tal como el monoclorhidrato de 2-((1-(2-(4-fluorofenil)-2-oxoetil) piperidin-4-il)metil)isoindolin-1-ona dihidratado, denominado tambien como la Forma (A) del compuesto (I).HCl.2H2O; donde dicha forma comprende picos de difraccion de rayos X en polvo 2(theta) los cuales son: 7.6°, 11.2°, 14.3°, 14.7°,14.9°, 18.6°, 22.0°, 25.9° 27.5° y 30.1°. Tambien se refiere a una formulacion farmaceutica util en el tratamiento de la esquizofrenia.
PE2017000948A 2014-12-02 2015-11-30 Composiciones que comprenden 2-((1-(2(4-fluorofenil)-2-oxoetil)piperidin-4-il)metil)isoindolin-1-ona para tratar la esquizofrenia PE20171646A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462086691P 2014-12-02 2014-12-02
US201562248071P 2015-10-29 2015-10-29

Publications (1)

Publication Number Publication Date
PE20171646A1 true PE20171646A1 (es) 2017-11-13

Family

ID=54848909

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2017000948A PE20171646A1 (es) 2014-12-02 2015-11-30 Composiciones que comprenden 2-((1-(2(4-fluorofenil)-2-oxoetil)piperidin-4-il)metil)isoindolin-1-ona para tratar la esquizofrenia

Country Status (26)

Country Link
US (6) US9458130B2 (es)
EP (2) EP4063357A1 (es)
JP (3) JP2018501217A (es)
KR (1) KR102620681B1 (es)
CN (2) CN111110677A (es)
AU (4) AU2015355226B2 (es)
BR (1) BR112017011555B1 (es)
CA (1) CA2968977A1 (es)
CL (2) CL2017001376A1 (es)
CO (1) CO2017005498A2 (es)
DK (1) DK3227273T3 (es)
EA (1) EA201791226A1 (es)
ES (1) ES2910528T3 (es)
HU (1) HUE058212T2 (es)
IL (3) IL280052B2 (es)
MX (1) MX2017007065A (es)
MY (1) MY185516A (es)
PE (1) PE20171646A1 (es)
PH (1) PH12017501007A1 (es)
PL (1) PL3227273T3 (es)
PT (1) PT3227273T (es)
SG (1) SG11201704332YA (es)
TW (1) TWI694069B (es)
UA (1) UA122780C2 (es)
WO (1) WO2016089766A1 (es)
ZA (1) ZA201703481B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3227273T3 (da) * 2014-12-02 2022-05-02 Minerva Neurosciences Inc Sammensætninger, som omfatter 2-((1-(2(4-fluorphenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-on, til behanlding af skizofreni
CN113908156A (zh) * 2016-05-25 2022-01-11 田边三菱制药株式会社 用于治疗非精神分裂症患者中的阴性症状的组合物和方法
AU2018290287B2 (en) * 2017-06-21 2024-06-13 Minerva Neurosciences, Inc. Gastro-resistant controlled release oral dosage forms
CN107721988A (zh) * 2017-10-31 2018-02-23 无锡福祈制药有限公司 具有抗炎活性的异吲哚‑1‑酮类化合物
CN112955219A (zh) * 2018-08-21 2021-06-11 密涅瓦神经科学有限公司 鲁潘立酮治疗阴性症状和病症、增加神经可塑性和促进神经保护的用途
EP3990113A1 (en) 2019-06-28 2022-05-04 Teva Czech Industries s.r.o. Solid state forms of roluperidone and salts thereof
US20230190870A1 (en) 2020-05-20 2023-06-22 The Board Of Trustees Of The University Of Illinois Method for Treating Lysosomal Storage Diseases with Histatin Peptides
WO2023154927A1 (en) 2022-02-14 2023-08-17 Minerva Neurosciences, Inc. Use of roluperidone in preventing relapse in schizophrenia patients

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
EP0325063B1 (en) 1988-01-21 1994-03-09 Merrell Dow Pharmaceuticals Inc. Use of 1,4-disubstituted-piperidinyl compounds in the manufacture of a medicament for the treatment of insomnia
WO1991006297A1 (en) 1989-10-27 1991-05-16 The Du Pont Merck Pharmaceutical Company (n-phthalimidoalkyl) piperidines
FR2797643B1 (fr) 1999-08-17 2003-06-06 Rhodia Chimie Sa Utilisation composes terpeniques polyoxypropylenes/ polyoxyethylenes comme agent de degraissage de surfaces dures
DK1260512T3 (da) * 2000-02-29 2007-11-05 Mitsubishi Pharma Corp Hidtil ukendte, cykliske amidderivater
JP4330343B2 (ja) * 2001-03-26 2009-09-16 ノバルティス アクチエンゲゼルシャフト 低水溶性活性成分、界面活性剤および水溶性ポリマーを含んでなる医薬組成物
CA2609969C (en) 2005-06-06 2015-10-27 Merck Sharp & Dohme Limited Cyclohexanesulfonyl derivatives as glyt1 inhibitors to treat schizophrenia
CA2569776A1 (en) * 2006-02-17 2007-08-17 Kos Life Sciences, Inc. Low flush niacin formulation
GB2462611A (en) 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
PT2595485T (pt) * 2010-07-20 2022-05-30 Minerva Neurosciences Inc Métodos de utilização de derivados amida cíclica para tratar distúrbios mediados pelo recetor sigma
US8937900B2 (en) * 2010-07-20 2015-01-20 Qualcomm Incorporated Enhancing pilot channel transmission in TD-SCDMA multicarrier systems using secondary carrier frequencies
BR112013001303A2 (pt) * 2010-07-20 2016-05-17 Cyrenaic Pharmaceuticals Inc métodos de uso de derivados de amida cíclica para tratar esquizofrenia
EP2468264A1 (en) 2010-12-27 2012-06-27 Laboratorios Liconsa, S.A. Oral pharmaceutical tablet for controled release of mesalazine and process for obtaining it
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
KR20140045925A (ko) * 2011-03-17 2014-04-17 루핀 리미티드 선택적 세로토닌 재흡수 억제제의 방출조절형 약제학적 조성물
WO2015191554A1 (en) 2014-06-09 2015-12-17 Intra-Cellular Therapies, Inc. Compounds and methods of use to treat schizophrenia
DK3227273T3 (da) 2014-12-02 2022-05-02 Minerva Neurosciences Inc Sammensætninger, som omfatter 2-((1-(2(4-fluorphenyl)-2-oxoethyl)piperidin-4-yl)methyl)isoindolin-1-on, til behanlding af skizofreni
CN113908156A (zh) 2016-05-25 2022-01-11 田边三菱制药株式会社 用于治疗非精神分裂症患者中的阴性症状的组合物和方法
AU2018290287B2 (en) 2017-06-21 2024-06-13 Minerva Neurosciences, Inc. Gastro-resistant controlled release oral dosage forms
CN112955219A (zh) 2018-08-21 2021-06-11 密涅瓦神经科学有限公司 鲁潘立酮治疗阴性症状和病症、增加神经可塑性和促进神经保护的用途

Also Published As

Publication number Publication date
US20200022968A1 (en) 2020-01-23
AU2023258386A1 (en) 2023-11-23
PH12017501007A1 (en) 2017-12-18
BR112017011555B1 (pt) 2023-10-03
AU2015355226B2 (en) 2020-04-02
IL301320A (en) 2023-05-01
CN107567444A (zh) 2018-01-09
TWI694069B (zh) 2020-05-21
IL280052B2 (en) 2023-09-01
CO2017005498A2 (es) 2017-09-20
NZ770365A (en) 2023-10-27
US9458130B2 (en) 2016-10-04
DK3227273T3 (da) 2022-05-02
CL2021000044A1 (es) 2021-06-04
PL3227273T3 (pl) 2022-05-30
EP3227273B1 (en) 2022-02-09
US9730920B2 (en) 2017-08-15
IL252347B (en) 2021-01-31
WO2016089766A1 (en) 2016-06-09
EA201791226A1 (ru) 2017-09-29
EP4063357A1 (en) 2022-09-28
AU2020204286A1 (en) 2020-07-16
SG11201704332YA (en) 2017-06-29
IL252347A0 (en) 2017-07-31
AU2021229240B2 (en) 2023-08-24
PT3227273T (pt) 2022-04-06
TW201632511A (zh) 2016-09-16
CL2017001376A1 (es) 2018-02-16
AU2021229240A1 (en) 2021-10-07
JP2022105159A (ja) 2022-07-12
ES2910528T3 (es) 2022-05-12
UA122780C2 (uk) 2021-01-06
HUE058212T2 (hu) 2022-07-28
US20160152597A1 (en) 2016-06-02
JP2020172531A (ja) 2020-10-22
EP3227273A1 (en) 2017-10-11
CA2968977A1 (en) 2016-06-09
KR20170106310A (ko) 2017-09-20
IL280052B1 (en) 2023-05-01
IL280052A (en) 2021-03-01
AU2015355226A1 (en) 2017-06-08
MX2017007065A (es) 2017-12-18
US10799493B2 (en) 2020-10-13
US20230201184A1 (en) 2023-06-29
US20170042877A1 (en) 2017-02-16
NZ732033A (en) 2023-10-27
US20210228561A1 (en) 2021-07-29
CN111110677A (zh) 2020-05-08
MY185516A (en) 2021-05-19
JP2018501217A (ja) 2018-01-18
AU2020204286B2 (en) 2021-06-17
KR102620681B1 (ko) 2024-01-04
US20180153871A1 (en) 2018-06-07
US10258614B2 (en) 2019-04-16
ZA201703481B (en) 2023-12-20
JP7069253B2 (ja) 2022-05-17
BR112017011555A2 (pt) 2018-01-09

Similar Documents

Publication Publication Date Title
PE20171646A1 (es) Composiciones que comprenden 2-((1-(2(4-fluorofenil)-2-oxoetil)piperidin-4-il)metil)isoindolin-1-ona para tratar la esquizofrenia
CL2016002072A1 (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
ECSP16076566A (es) Compuestos de heteroarilo o arilo biciclicos fusionados y su aplicación a inhibidores de irak4
TW201613872A (en) IRAK4 inhibiting agents
MX2016013689A (es) Compuestos 4-amino-imidazoquinolina.
PH12016502378A1 (en) Substituted dihydroisoquinolinone compounds
CO2018000589A2 (es) Oxiesteroles y composiciones farmacéuticas que los contienen
PH12016501791B1 (en) Muscarinic receptor agonists
UY35684A (es) Formulación de inhibidores de la tirosina quinasa de bazo (syk)
UY34750A (es) ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?.
MX2017008518A (es) Compuestos de isoquinolina para el tratamiento de virus de inmunodeficiencia humana (vih).
DOP2015000201A (es) Compuestos de azabencimidazol como inhibidores de pde4 isoenzimas para el tratamiento del snc y otros trastornos
CL2017001650A1 (es) Derivados de 5-[(piperazina-1-yl)-3-oxo-propilo]-imidazolidina-2,4-dionan como inhibidores adamts para el tratamiento oesteoartritis.
CL2015002897A1 (es) Inhibidores de bace1
EA201790627A1 (ru) СТИМУЛЯТОРЫ рГЦ
SG11201610217YA (en) 2-(3-pyridinyl)-1h-benzimidazole derivative compound and medicine containing same
DK3103453T3 (da) Medicinsk sammensætning omfattende heterocyklisk diamino-carboxamidforbindelse som aktiv bestanddel
ZA201704462B (en) New benzimidazole derivatives as antihistamine agents
MX2015012153A (es) Inhibidores de la quinasa pirrolopirimidina cdk9.
CU20150065A7 (es) Compuestos derivados de bencil 4-((2-(triazol-5-il)acetamido)metil)piperidin-1- carboxilato activos como inhibidores de autotaxina
MX2016010549A (es) Indol- y bencimidazolcarboxamidas como insecticidas y acaricidas.